- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02616874
Study to Evaluate the Safety and Effect of HIVconsv Vaccines in Combination With Histone Deacetylase Inhibitor Romidepsin on the Viral Rebound Kinetic After Treatment Interruption in Early Treated HIV-1 Infected Individuals
January 16, 2018 updated by: IrsiCaixa
An Open Label Phase I Trial to Evaluate the Safety and Effect of HIVconsv Vaccines in Combination With Histone Deacetylase Inhibitor Romidepsin on the Viral Rebound Kinetic After Treatment Interruption in Early Treated HIV-1 Infected Individuals (BCN02-Romi)
The BCN02-Romi study aims to evaluate a combined "kick and kill" strategy using the most immunogenic candidate vaccine available so far (HIVconsv) with the strongest latency reversal agent available at present time (romidepsin) in a cohort of early-treated HIV positive individuals.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
The combined use of therapeutic vaccination and specific drugs that can reactivate latent virus from the reservoir (Kick and kill strategies) hold the promise to achieve functional cure and viral eradication of HIV infection.
The present project consists of a proof-of-concept clinical trial in a cohort of 24 early treated HIV-1 infected individuals rolled-over from the BCN01 vaccine clinical trial in which participants received the most immunogenic vaccines tested to date, ChAd and modified vaccinia Ankara (MVA).HIVconsv vaccines.
All individuals will be given a booster immunization with MVA.HIVconsv in combination with romidepsin (RMD), a potent histone deacetylation inhibitor (HDACi) and will later undergo a monitored antiretroviral pause.
HIVconsv vaccines have specifically been designed to stimulate a broad and potent cytotoxic T cell (CTL) response towards the most conserved viral regions of the HIV-1 proteome, which have recently been suggested to have a crucial role when targeting HIV variants harboured in the latent reservoir with mutations to escape T-cell immune responses.
The study includes the development of a population pharmacokinetic/pharmacodynamic (PK/PD) substudy to analyse the in vivo effects of RMD in the induction of HIV expression in resting cells, deeply investigate any unintended effect on the CTL function as well as predict the relationship between RMD exposure and such effects.
The investigators' results will allow investigators to optimize RMD dosing, to evaluate the clinical efficacy of this eradication strategy after the cART interruption and to identify better correlates of control of rebound viremia after cessation of treatment.
Study Type
Interventional
Enrollment (Actual)
15
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Barcelona, Spain, 08036
- Clinic Hospital
-
-
Barcelona
-
Badalona, Barcelona, Spain, 08916
- Germans Trias I Pujol Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years to 97 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Subject included in ChAd-MVA.HIVconsv_BCN01 study with complete follow-up and included in BCN01-RO extension study.
- Optimal virological suppression for at least 3 years.cop/ml).
- Being on a non-boosted integrase-inhibitor based regimen (raltegravir or dolutegravir) for at least 4 weeks at screening visit.
Haematological and biochemical laboratory parameters as follows:
- Haemoglobin > 10g/dl
- Platelets > 100.000/dl
- Alanine aminotransferase (ALT) ≤ 2.5 x upper limit of normal (ULN)
- Creatinine ≤ 1.3 x ULN
- CD4 T cell count ≥500 cells/mm3
Exclusion Criteria:
- Positive pregnancy test.
- Presence of resistance drug mutations in the screening genotype
- History of autoimmune disease other than HIV-related auto-immune disease.
- Treatment for cancer or lymphoproliferative disease within 1 year of study entry
- Any other prior therapy which, in the opinion of the investigators, would make the individual unsuitable for the study or influence the results of the study
- Current or recent use (within last 3 months) of interferon or systemic corticosteroids or other immunosuppressive agents
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: MVA.HIVconsv plus romidepsin
|
Dose: 2x10e8 pfu, Interval: weeks 0 and 9.
Dose: 5mg/m2 over 4hours, Interval: weeks 3, 4 and 5
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of participants with grade >=3 adverse events assessed by Division of AIDS (DAIDS) grading table
Time Frame: Through study completion, maximum 75 weeks
|
Grade >=3 adverse events
|
Through study completion, maximum 75 weeks
|
Number of participants with serious adverse events
Time Frame: Through study completion, maximum 75 weeks
|
Serious adverse events
|
Through study completion, maximum 75 weeks
|
Viral reservoir measured by total HIV-1 DNA copies per 10e6 CD4+ T cells
Time Frame: From baseline to visit week 6 (romidepsin 3 + 1 week)
|
Total HIV-1 DNA copies per 10e6 CD4+ T cells
|
From baseline to visit week 6 (romidepsin 3 + 1 week)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Romidepsin Cmax
Time Frame: week 3
|
RMD plasma concentrations will be measured by Liquid chromatography-mass spectrometry (LC-MS/MS)
|
week 3
|
Romidepsin Cmax
Time Frame: week 4
|
RMD plasma concentrations will be measured by LC-MS/MS
|
week 4
|
Romidepsin Cmax
Time Frame: week 5
|
RMD plasma concentrations will be measured by LC-MS/MS
|
week 5
|
Romidepsin Cmin
Time Frame: week 3
|
RMD plasma concentrations will be measured by LC-MS/MS
|
week 3
|
Romidepsin Cmin
Time Frame: week 4
|
RMD plasma concentrations will be measured by LC-MS/MS
|
week 4
|
Romidepsin Cmin
Time Frame: week 5
|
RMD plasma concentrations will be measured by LC-MS/MS
|
week 5
|
Romidepsin area under curve (AUC)
Time Frame: week 3
|
RMD plasma concentrations will be measured by LC-MS/MS
|
week 3
|
Romidepsin AUC
Time Frame: week 4
|
RMD plasma concentrations will be measured by LC-MS/MS
|
week 4
|
Romidepsin AUC
Time Frame: week 5
|
RMD plasma concentrations will be measured by LC-MS/MS
|
week 5
|
HIV-1 expression in resting CD4+ T-cells measured by CA-RNA and single-copy assay (SCA)
Time Frame: week 6
|
week 6
|
|
Levels of Histone H3 acetylation in lymphocytes
Time Frame: week 6
|
week 6
|
|
CTL toxicity assessment based on viability, activation or exhaustion (most relevant marker according to previous studies)
Time Frame: week 6
|
week 6
|
|
HIVconsv-specific T cell responses will be measured by IFNg ELISPOT using peptide pools covering different HIV proteins and HIVcons sequences.
Time Frame: week 6
|
week 6
|
|
Viral suppressive capacity of CD8+ T cells in vitro, using a flow cytometric assay
Time Frame: Baseline
|
Baseline
|
|
Viral suppressive capacity of CD8+ T cells in vitro, using a flow cytometric assay
Time Frame: Week 17
|
Week 17
|
|
Proportion of individuals who initiate a MAP following the futility analysis
Time Frame: Week 17
|
Week 17
|
|
Proportion of individuals who maintain sustained plasma viral load (pVL) <2,000 copies/ml
Time Frame: Week 29
|
Week 29
|
|
Proportion of individuals in whom cART is reinitiated due to viral rebound
Time Frame: Up to 51 weeks
|
Up to 51 weeks
|
|
Emergence of viral resistance during MAP phase
Time Frame: Up to 51 weeks
|
Description of viral resistance emerged, genotype.
|
Up to 51 weeks
|
Proportion of patients with viral suppression 6 months after treatment resumption.
Time Frame: 24 weeks after treatment resumption (up to 75 weeks).
|
24 weeks after treatment resumption (up to 75 weeks).
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
February 1, 2016
Primary Completion (Actual)
September 1, 2016
Study Completion (Actual)
October 30, 2017
Study Registration Dates
First Submitted
November 9, 2015
First Submitted That Met QC Criteria
November 25, 2015
First Posted (Estimate)
November 30, 2015
Study Record Updates
Last Update Posted (Actual)
January 17, 2018
Last Update Submitted That Met QC Criteria
January 16, 2018
Last Verified
January 1, 2018
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- BCN02-Romi
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HIV
-
University of Alabama at BirminghamMobile County Health Deparment; Alabama Department of Public HealthRecruitingHIV | HIV Testing | HIV Linkage to Care | HIV TreatmentUnited States
-
French National Agency for Research on AIDS and...Elizabeth Glaser Pediatric AIDS FoundationCompletedPartner HIV Testing | Couple HIV Counseling | Couple Communication | HIV IncidenceCameroon, Dominican Republic, Georgia, India
-
ANRS, Emerging Infectious DiseasesHopital Universitaire Robert-Debre; Institut de Recherche pour le Developpement and other collaboratorsUnknownHIV | HIV-uninfected Children | Children Exposed to HIVCameroon
-
University of MinnesotaWithdrawnHIV Infections | HIV/AIDS | Hiv | AIDS | Aids/Hiv Problem | AIDS and InfectionsUnited States
-
CDC FoundationGilead SciencesUnknownHIV Preexposure Prophylaxis | HIV ChemoprophylaxisUnited States
-
Africa Health Research InstituteLondon School of Hygiene and Tropical Medicine; University College, London; University... and other collaboratorsRecruiting
-
Massachusetts General HospitalNational Institute of Mental Health (NIMH); Fenway Community Health; Tuberculosis...CompletedHIV/STI Risk | HIV/STI IncidenceUnited States, India
-
Erasmus Medical CenterNot yet recruitingHIV Infections | Hiv | HIV-1-infection | HIV I InfectionNetherlands
-
University of WashingtonNational Institute of Mental Health (NIMH)RecruitingHIV Prevention | HIV Preexposure Prophylaxis | ImplementationKenya
-
University of Maryland, BaltimoreWithdrawnHiv | Kidney Transplant | HIV Reservoir | CCR5United States
Clinical Trials on MVA.HIVconsv vaccine
-
University of OxfordMedical Research CouncilTerminatedHIV-1United Kingdom
-
University of OxfordGlaxoSmithKline; ReiThera SrlCompletedHIV Infection | Hepatitis C InfectionUnited Kingdom
-
University College, LondonGlaxoSmithKline; Medical Research Council; University of OxfordCompleted
-
University of OxfordKarolinska Institutet; University of Nairobi; International AIDS Vaccine Initiative and other collaboratorsCompleted
-
University of OxfordCompleted
-
Butantan InstituteUniversity of Sao Paulo; Hospital Universitario da USPCompleted
-
Sinovac Biotech Co., LtdCompleted
-
GlaxoSmithKlineCompletedMalaria | Malaria VaccinesGhana, Burkina Faso
-
University of OxfordMalaria Research and Training Center, Bamako, MaliRecruiting
-
GlaxoSmithKlineIQVIA, USAActive, not recruitingChickenpoxTaiwan, Poland, United States, Estonia, Puerto Rico, Mexico